Department of Neurobiology, Care Sciences, and Society, Karolinska Institutet, Stockholm, Sweden.
Acta Neurol Scand. 2012 Feb;125(2):142-7. doi: 10.1111/j.1600-0404.2011.01517.x. Epub 2011 Apr 6.
Parkinson's disease (PD) is a chronic neurodegenerative disease expected to cause great costs. The aim of this study was to calculate drug and treatment costs in patients with PD in Sweden.
All healthcare contacts of patients with PD in Stockholm County, Sweden, were extracted from registers together with information on reimbursements from the authorities to the caregivers. PD-related costs were calculated together with non-PD-related costs. Cost per patient was calculated and extrapolated to the whole Swedish population, taking population demographics into consideration. In addition, nationwide PD drug sales statistics were included.
The PD prevalence of Stockholm County was estimated to 196 per 100,000 inhabitants, resulting in an estimated total of about 22,000 patients with PD in Sweden. The cost per patient was estimated to SEK 76,000 of which drug costs accounted for SEK 15,880. The annual direct costs in patients with PD in Sweden were SEK 1.7 billion in 2009.
Our study estimates high direct costs in patients with PD in Sweden, SEK 1.7 billion, 52% for inpatient care, 27% for outpatient care and 21% for drugs. With an ageing population and the medical progress, the financial burden on society will most probably increase in the future. This study might initiate and provide information for discussions about future cost allocations and healthcare priorities.
帕金森病（PD）是一种慢性神经退行性疾病，预计会带来巨大的成本。本研究旨在计算瑞典 PD 患者的药物和治疗费用。
从瑞典斯德哥尔摩县的登记处提取了所有 PD 患者的医疗接触信息，并附有当局向护理人员报销的信息。计算了 PD 相关成本和非 PD 相关成本。考虑到人口统计学因素，计算了每位患者的费用并将其外推到整个瑞典人口。此外，还纳入了全国范围内的 PD 药物销售统计数据。
斯德哥尔摩县的 PD 患病率估计为每 10 万人中有 196 人，因此瑞典大约有 22000 名 PD 患者。每位患者的费用估计为 76000 瑞典克朗，其中药物费用为 15880 瑞典克朗。2009 年瑞典 PD 患者的直接年度费用为 17 亿瑞典克朗。
我们的研究估计瑞典 PD 患者的直接费用很高，为 17 亿瑞典克朗，其中 52%用于住院治疗，27%用于门诊治疗，21%用于药物治疗。随着人口老龄化和医疗进步，未来社会的财务负担很可能会增加。本研究可能会引发并提供有关未来成本分配和医疗保健重点的讨论信息。
